Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Oscar Lambret
With
National Cancer Institute, France
The aim of this study is to assess the safety of hypofractionated stereotactic boost radiation (prostate) after normofractionated radiotherapy (prostate + seminal vesicles).
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Prostate adenocarcinoma proved by histology
With at least one of this intermediate-risk criterias:
* T2b
* and/or PSA between 10 et 20 ng/ml
* and/or Gleason score = 7
Prostatic volume ≤ 80 cc
No adenopathy(lymph node \< 1.5 cm on scanner or MRI and/or in lymph node dissection)
No metastasis (bone scan)
Age \>= 18 ans
No prior pelvic irradiation
No prior anticancer treatment (prostatectomy, chemotherapy, hormonotherapy \> 3 months)
Performance status (ECOG) \< 1
No contraindication of fiducials implantation, hemostasis disorders must be treated before the implantation
